SOURCE: Proteonomix

Proteonomix

January 27, 2012 08:20 ET

PROTEONOMIX, INC.'s (PROT) CEO to Present at Investor Summit 2012 Sponsored by Merriman Capital in New York on February 1, 2012

MOUNTAINSIDE, NJ--(Marketwire - Jan 27, 2012) - PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it will be presenting at the Investor Summit 2012 on February 1, 2012, sponsored by Merriman Capital at the Intercontinental Time Square Hotel in New York City.

Michael Cohen, President of the Company, stated: "We thank Merriman Capital for the opportunity address the investment community regarding the Company's UMK 121 technology. The Company will address the use of the technology in the emerging markets, particularly in Africa where large numbers of cases of severe cirrhosis and accompanying End Stage Liver Disease exist."

Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is advancing toward its first clinical trial in ESLD ("End Stage Liver Disease") patients. In addition we intend to highlight other parts of our company of interest to the investment community including our Proteoderm cosmeceutical subsidiary and StromaCel."

About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact Information

  • Contact:
    Proteonomix, Inc.
    Michael Cohen
    CEO
    Phone: +1-973-544-6116
    Email: Email Contact